The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis
Open accessAbstract
Kynurenic acid (KYNA) is an endogenous antagonist of N-methyl-D-aspartate and α7 nicotinic acetylcholine receptors that is derived from astrocytes as part of the kynurenine pathway of tryptophan degradation. Evidence suggests that abnormal KYNA levels are involved in the pathophysiology of schizophrenia. However, this has never been assessed through a meta-analysis. A literature search was conducted through Ovid using Embase, Medline, and PsycINFO databases (last search: December 2016) with the search terms: (kynuren* or KYNA) and (schizophreni* or psychosis). English language studies measuring KYNA levels using any method in patients with schizophrenia and healthy controls (HCs) were identified. Standardized mean differences (SMDs) were calculated to determine differences in KYNA levels between groups. Subgroup analyses were separately performed for nonoverlapping participant samples, KYNA measurement techniques, and KYNA sample source. The influences of patients' age, antipsychotic status (%medicated), and sex (%male) on study SMDs were assessed through a meta-regression. Thirteen studies were deemed eligible for inclusion in the meta-analysis. In the main analysis, KYNA levels were elevated in the patient group. Subgroup analyses demonstrated that KYNA levels were increased in nonoverlapping participant samples, and centrally (cerebrospinal fluid and brain tissue) but not peripherally. Patients' age, %medicated, and %male were each positively associated with study SMDs. Overall, KYNA levels are increased in patients with schizophrenia, specifically within the central nervous system. An improved understanding of KYNA in patients with schizophrenia may contribute to the development of novel diagnostic approaches and therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Kim, S. Y., Park, J. E., Lee, Y. J., Seo, H.-J., Sheen, S.-S., Hahn, S., Jang, B.-H., & Son, H.-J. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.09.016 · Cited by 1,165
Seeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
Upthegrove, R., Manzanares-Teson, N., & Barnes, N. M. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.005 · Cited by 501
Lugo-Huitrón, R., Blanco-Ayala, T., Ugalde-Muñiz, P., Carrillo-Mora, P., Pedraza-Chaverrí, J., Silva-Adaya, D., Maldonado, P. D., Torres, I., Pinzón, E., Ortiz-Islas, E., et al. (2011) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2011.07.002 · Cited by 346
Cited by
Tryptophan metabolism in health and disease
Xue, C., Li, G., Zheng, Q., Gu, X., Shi, Q., Su, Y., Chu, Q., Yuan, X., Bao, Z., Lu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.004 · Cited by 961
The kynurenine pathway: a finger in every pie
Savitz, J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0414-4 · Cited by 756
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Metagenome-wide association of gut microbiome features for schizophrenia
Zhu, F., Ju, Y., Wang, W., Wang, Q., Guo, R., Ma, Q., Sun, Q., Fan, Y., Xie, Y., Yang, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15457-9 · Cited by 409
Glutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
Metadata
- Authors
- Plitman, E., Iwata, Y., Caravaggio, F., Nakajima, S., Chung, J. K., Gerretsen, P., Kim, J., Takeuchi, H., Chakravarty, M. M., Remington, G., & Graff-Guerrero, A.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-02-10
- Volume
- 43
- Issue
- 4
- Pages
- 764-777
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2586728661
- Cited by
- 251
- References
- 15
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1093/schbul/sbw221
- The paper
- Plitman, E., Iwata, Y., Caravaggio, F., Nakajima, S., Chung, J. K., Gerretsen, P., Kim, J., Takeuchi, H., Chakravarty, M. M., Remington, G., & Graff-Guerrero, A. (2017). Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbw221
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.